NEW YORK—Covington has advised Sensyne Health, the British clinical AI technology company, on its agreement with Jefferson Health to evaluate the clinical and commercial potential of its GDm-Health™ system in the United States.
GDm-Health is a direct patient-to-clinician blood glucose monitoring management system specifically designed for the management of gestational diabetes and can be used to help women manage pre-existing diabetes. The system allows clinician review of patient-annotated blood glucose results in real time. It is based on a smartphone application that enables women to connect a blood glucose meter to their smartphone using Bluetooth or NFC (near field communication) and then automatically collecting blood glucose measurements.
Under the terms of the agreement, Sensyne Health will collaborate with Jefferson Health’s Department of Obstetrics and Gynaecology on a 12-month multi-phase Clinical and Health Economic Evaluation of the GDm-Health™ product in the Jefferson Health System Hospitals in Pennsylvania and New Jersey. Sensyne Health will have the right to analyze, using its proprietary clinical AI technology, the anonymized and de-identified patient data generated during the evaluation to help uncover new insights and address areas of unmet medical need in women’s health.
Covington has handled a range of transactions and regulatory matters for Sensyne Health, including in connection with its £60 million IPO on London’s AIM market and negotiating strategic agreements with three UK National Health Service Trusts.
Working together with Sensyne Health’s in-house legal team, Covington’s multi-jurisdictional, multi-disciplinary team was led by Nigel Howard in Covington’s New York office, and included T’Shae Sherman, Josh Gray, Anna Kraus, and Daniel Pavin, all members of the firm’s digital health group.
Back
